1. Medtech Insight
  2. >>Archive

HRS 2014 Roundup

The 2014 Heart Rhythm Society Scientific Sessions ended May 10 in San Francisco with a big study from Boston Scientific on the benefits of implantable cardioverter defibrillator remote monitoring, and data on a smartphone-enabled electrocardiogram and the use of a spinal stimulator for heart failure patients. Earlier in the meeting, data were reported on the success of pacemaker remote monitoring and other studies.

The 2014 Heart Rhythm Society Scientific Sessions ended May 10 in San Francisco with a big study from Boston Scientific Corp. on the benefits of implantable cardioverter defibrillator remote monitoring. Results of the PREDICt-RM study show that remote monitoring with the firm’s Latitude Patient Monitoring System reduces mortality and hospitalization rates. PREDICt-RM combined data from Boston Scientific’s ALTITUDE Registry and the National Cardiovascular Data Registry ICD Registry to follow 37,742 first-time ICD or cardiac resynchronization therapy (CRT)-defibrillator patients for at least three years post-implant. The investigators compared all-cause mortality and hospitalization rates in patients who used remote monitoring and those who did not take advantage of remote monitoring even though their ICD was compatible with Latitude.

During the three-year follow-up period, results from PREDICt-RM showed that patients whose doctors monitored their ICD or CRT-D with Latitude...

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Even ‘Small’ Leaks After Left Atrial Appendage Occlusion Raises Stroke Risk, Study Finds

 
• By Brian Bossetta

A Japanese study of Watchman LAA closure devices found that leaks of any size after implantation raise the risk of stroke. The study comes shortly after the US FDA issued an early alert for the Watchman access systems.

23andMe Genetic Tests Among 12 New FDA Classifications

 
• By Elizabeth Orr

A late-August batch of device classifications from the US FDA includes genetic tests from 23andMe, hand-held spinal surgery tools, and several IVDs.

German Hospital Reform Risks Spiraling Out Of Control

 
• By Ashley Yeo

Amendments to Germany’s – barely in force – health reform law will be decided after the summer break. The new DRGs payments plan and service groups will be reviewed, but critics fear for the law’s future.